Biotech Values

[Biowatch]

AZN to buy Fusion for $2.4 billion

Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities

Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR

https://finance.yahoo.com/news/fusion-pharmaceuticals-acquired-astrazeneca-accelerating-070000564.html